The association of LAG-3-and PD-1-inhibitors may be able to overcome resistance and enhance responses, as suggested by preliminary results of the CA224-020 clinical trial (NCT01968109) including melanoma patients progressed on prior anti-PD-1/PD-L1 therapy. Here, LAG3 is linked to melanoma.